lifestyle.californiaconsumerbanking.com

Author: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

May 14, 2026
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 9, 2026
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

April 29, 2026
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 24, 2026
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 10, 2026
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

March 10, 2026
Aardvark Therapeutics Announces Leadership Appointments

March 10, 2026
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

March 9, 2026